MedTrace Logo

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

NCT02732899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-02-14

Study results available
· View outcomes & findings →

Summary

To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous intravitreal anti-vascular endothelial growth factor (antiVEGF) treatment.

Conditions

  • Exudative Age Related Macular Degeneration

Interventions

DRUG

Sirolimus

DRUG

EYLEA

Sponsors & Collaborators

  • Maturi, Raj K., M.D., P.C.

    lead INDIV

Principal Investigators

  • Raj K Maturi, MD · Raj K. Maturi, MD, PC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-03-20
Completion
2017-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02732899 on ClinicalTrials.gov